Prestige BioPharma Shares Fall 21.4% in Five Trading Days on Heavy Volume

What happened

From 2026-10-22 to 2026-10-28 the shares fell 21.4% on volume 5.7 times normal. The close on 2026-10-28 was ₩4,220, against ₩5,690 on 2026-10-16, the date of the previous report. Market value is now about ₩253.6B, versus about ₩341.9B then.

The stock is down 30.4% over one month, 24.0% over three months and 67.5% over one year. It sits near the bottom of its 52-week range (low ₩3,910, high ₩14,120).

No filing excerpts or news headlines are available for this move, so the cause is not known from the data. The latest filings are from September 2026: the annual report and its amendment, the shareholders' meeting results, auditor and independent director changes, and a change in the largest shareholder's holdings. None is tied to this drop in the data.

Over 20 days, foreign investors were net sellers of about ₩73.1M, institutions net buyers of about ₩2.4M and retail net buyers of about ₩46.4M. Foreign ownership is 63.7%, unchanged from 60 days ago. Short balance is shown as 0.0%.

What it changes for the thesis

The previous report described an early commercial stage company: FY 2025 revenue of about ₩10.2M, an operating loss of about ₩48.0M, and a market value far above what sales support. Nothing in the data changes those fundamentals, and no new financial results are available.

The sharp fall shows how sensitive the share price is to expectations that the filings do not show. The previous report noted foreign selling and retail buying, and that pattern continues. Without a known trigger, the move should not be read as new information about the business.

What it changes for the valuation

The model still has no estimate for this company, and the previous report had none either, so there is no model estimate per share to compare with the ₩4,220 price.

Multiples have fallen with the price but remain extreme: P/E 15,950.8 (previously 21,507.1), P/B 836.9 (previously 1,128.5) and P/S 24,826.6 (previously 33,474.7). Peers trade far lower, for example Samsung Biologics at P/E 32.0 and P/B 7.6, Celltrion at 27.9 and 2.5, and Yuhan at 24.0 and 2.4. The gap to peers has narrowed only because the price fell, not because earnings or sales changed.

Closing view

The evidence shows a large, high-volume price decline with no identified cause in the filings or news provided. Operating losses, tiny revenue and the lack of a model estimate are unchanged from the previous report. The lower price reduces the market value but leaves multiples very high. Investors should wait for an explanation or new filings and form their own view.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

• Application for Appointment, Dismissal, or Change of External Auditor of Foreign Corporation Listed on KOSPISep 29, 2026
• Annual general meeting resultsSep 29, 2026
• Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsSep 29, 2026
• Amended: Annual report (Jun 2026)Sep 23, 2026
• Annual report (Jun 2026)Sep 22, 2026
• Audit report submittedSep 21, 2026
• Shareholders' meeting calledSep 14, 2026
• Notice of shareholders' meetingSep 14, 2026
• Change in largest shareholder's holdingsSep 1, 2026
• Insider shareholding reportSep 1, 2026
• 5%+ holding reportSep 1, 2026
• Amended: Major sales or supply contractAug 25, 2026
• Daily prices up to 2026-10-28
• Financial statements, trailing 12 months as of FY 2025

Report history

1. Oct 29, 2026Update noteBig price movePrestige BioPharma Shares Fall 21.4% in Five Trading Days on Heavy Volume
2. Oct 18, 2026InitiationStart of coverage (reader request)Prestige BioPharma: Tiny Revenue, Persistent Operating Losses and a Share Price Down 55.9% Over a Year